Vericel Corp
NASDAQ:VCEL

  • LAST PRICE
    54.0000
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    21.6000/ 2
  • Ask / Lots
    56.5300/ 1
  • Open / Previous Close
    --- / 54.0000
  • Day Range
    ---
  • 52 Week Range
    32.2800
    54.4700
  • Volume
    52

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 8, 2024

  • Nov 7, 2024

      Show headlines and story abstract

    • 9:48AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: VCEL
      09:48 AM EST, 11/07/2024 (MT Newswires) -- Vericel (VCEL) reported a Q3 net loss Thursday of $0.02 per diluted share, narrowing from a $0.08 net loss per share a year earlier. Analysts polled by Capital IQ expected a net loss of $0.05 per share. Rev...

    • 7:55AM ET on Thursday Nov 07, 2024 by MT Newswires
      Companies Mentioned: VCEL
      07:55 AM EST, 11/07/2024 (MT Newswires) -- ...

    • 7:55AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: VCEL

      or similar expressions.

      Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI, MACI Arthro, Epicel, and NexoBrid, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely completion of a new headquarters and manufacturing facility in Burlington, Massachusetts, the ability to achieve or sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA's potential approval of the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, changes in surgeon and hospital treatment prioritizations caused by the temporary shortage of essential medical supplies, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound's ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to, damage or disruption caused by natural disasters and the ongoing military conflicts in the Middle East region involving Israel, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and the Middle East conflicts, adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, global geopolitical tensions or record inflation and the potential future impacts on our business or the economy generally stemming from a public health emergency.

    • 7:55AM ET on Thursday Nov 07, 2024 by Dow Jones
      Companies Mentioned: VCEL

Peers Headlines